Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Toripalimab After Radiotherapy Alone in Elderly Esophageal Squamous Cell Carcinoma: A Prospective Phase II Clinical Trial
Authors not listed
The Central Hospital of Lishui City · 2023
Abstract
The incidence and mortality of esophageal squamous cell carcinoma are at the forefront in China.Most part of patients are elderly. Concurrent chemoradiotherapy is the standard treatment for unresectable locally advanced esophageal squamous cell carcinoma. Most elderly patients cannot tolerate concurrent chemotherapy because of complications and other reasons. Immunotherapy has definite efficacy and low toxicity in advanced esophageal squamous cell carcinoma, and the results combined with radiotherapy have also been preliminarily reported. Therefore, it is necessary to further explore the efficacy and safety of radiotherapy combined with immunotherapy in elderly patients with esophageal squamous cell carcinoma.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-05 MST
Cite this
APA
Anonymous. (2023). Toripalimab After Radiotherapy Alone in Elderly Esophageal Squamous Cell Carcinoma: A Prospective Phase II Clinical Trial. <em>The Central Hospital of Lishui City</em>. https://clinicaltrials.gov/study/NCT05791136
Vancouver
Anonymous. Toripalimab After Radiotherapy Alone in Elderly Esophageal Squamous Cell Carcinoma: A Prospective Phase II Clinical Trial. The Central Hospital of Lishui City. 2023.
BibTeX
@misc{anon2023Toripa,
title = {Toripalimab After Radiotherapy Alone in Elderly Esophageal Squamous Cell Carcinoma: A Prospective Phase II Clinical Trial},
author = {Anonymous},
journal = {The Central Hospital of Lishui City},
year = {2023},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Chinese Academy of Medical Sciences 2021
Open access · US-GOV
Radiotherapy Plus Durvalumab in Elderly Esophageal Squamous Cell Carcinoma: A Prospective Phase II Clinical Trial
Tianjin Medical University Cancer Institute and Hospital 2023
Open access · US-GOV
Tislelizumab Combined With Concurrent Chemoradiation Versus Concurrent Chemoradiation for Older Patients With Inoperable Locally Advanced Esophageal Squamous Cell Carcinoma: a Randomized, Parallel-controlled, Multicenter Phase II Clinical Study
The First Affiliated Hospital with Nanjing Medical University 2024
Open access · US-GOV
A Prospective, Randomized Controlled, Open Label, Multicenter, Phase II Clinical Study Evaluating the Efficacy and Safety of Nimotuzumab Combined With Concurrent Chemoradiotherapy in Elderly Patients With Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
Sun Yat-sen University 2015
Open access · US-GOV
A Prospective, Single-arm Study of Simultaneous Modulated Accelerated Radiotherapy Combined With S-1/DDP for Elderly Esophageal Squamous Cell Carcinoma.
Shanghai Chest Hospital 2024
Open access · US-GOV
Neoadjuvant PD-1 Blockade (Toripalimab) Monotherapy for Elderly Patients With Locally Advanced Resectable Esophageal Squamous Cell Carcinoma: a Phase II Trial
Sichuan University 2024
Open access · US-GOV